Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Value of Glucosylsphingosine (Lyso-Gb1) as a Biomarker in Gaucher Disease: A Systematic Literature Review
Shoshana Revel‐Vilk, Maria Fuller, Ari Zimran
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 19, pp. 7159-7159
Open Access | Times Cited: 78

Showing 26-50 of 78 citing articles:

Serum Phospholipid Profile Changes in Gaucher Disease and Parkinson’s Disease
Laura López de Frutos, Francisco Almeida, Jessica Murillo‐Saich, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10387-10387
Open Access | Times Cited: 11
Taliglucerase alfa in the longterm treatment of children and adolescents with type 1 Gaucher disease: the Albanian experience
Paskal Cullufi, Sonila Tomori, Virtut Velmishi, et al.
Frontiers in Pediatrics (2024) Vol. 12
Open Access | Times Cited: 2
A Brazilian Rare-Disease Center’s Experience with Glucosylsphingosine (lyso-Gb1) in Patients with Gaucher Disease: Exploring a Novel Correlation with IgG Levels in Plasma and a Biomarker Measurement in CSF
Matheus Vernet Machado Bressan Wilke, Gabrielle D. Iop, Larissa Faqueti, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2870-2870
Open Access | Times Cited: 2
Long- and Short-Term Glucosphingosine (lyso-Gb1) Dynamics in Gaucher Patients Undergoing Enzyme Replacement Therapy
Paweł Dubiela, Paulina Szymańska-Rożek, Piotr Hasiński, et al.
Biomolecules (2024) Vol. 14, Iss. 7, pp. 842-842
Open Access | Times Cited: 2
Gaucher disease type 3c: Expanding the clinical spectrum of an ultra‐rare disease
John S. Wang, Rebecca L. Koch, Daniel Kenney‐Jung, et al.
JIMD Reports (2024) Vol. 65, Iss. 5, pp. 313-322
Open Access | Times Cited: 2
Contribution of Glucosylsphingosine (Lyso-Gb1) to Treatment Decisions in Patients with Gaucher Disease
Tama Dinur, Peter Bauer, Christian Beetz, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 4, pp. 3945-3945
Open Access | Times Cited: 6
GAU-PED study for early diagnosis of Gaucher disease in children with splenomegaly and cytopenia
Andrea Pession, Maja Di Rocco, Francesco Venturelli, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 5
A new multiplex analysis of glucosylsphingosine and globotriaosylsphingosine in dried blood spots by tandem mass spectrometry
Amber Van Baelen, Laurence Roosens, Sylvie Devos, et al.
Molecular Genetics and Metabolism Reports (2023) Vol. 37, pp. 100993-100993
Open Access | Times Cited: 5
Lysosomal storage disorders: Clinical and therapeutic aspects
Gregory M. Pastores
Handbook of clinical neurology (2023), pp. 557-567
Closed Access | Times Cited: 5
Insights into the Value of Lyso-Gb1 as a Predictive Biomarker in Treatment-Naïve Patients with Gaucher Disease Type 1 in the LYSO-PROOF Study
Filipa Curado, Sabine Rösner, Susanne Zielke, et al.
Diagnostics (2023) Vol. 13, Iss. 17, pp. 2812-2812
Open Access | Times Cited: 5
Noninvasive DBS-Based Approaches to Assist Clinical Diagnosis and Treatment Monitoring of Gaucher Disease
Cláudia Rossi, Rossella Ferrante, Silvia Valentinuzzi, et al.
Biomedicines (2023) Vol. 11, Iss. 10, pp. 2672-2672
Open Access | Times Cited: 5
TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease
Margarita M. Ivanova, Julia Dao, Lauren Noll, et al.
Journal of Clinical Medicine (2021) Vol. 10, Iss. 10, pp. 2217-2217
Open Access | Times Cited: 12
Identification of a novel therapeutic target underlying atypical manifestation of Gaucher disease
Eun Na Kim, Hyo‐Sang Do, Hwangkyo Jeong, et al.
Clinical and Translational Medicine (2022) Vol. 12, Iss. 5
Open Access | Times Cited: 8
Rapid home therapy infusion of velaglucerase alfa in naïve patients with Gaucher disease
Michal Becker‐Cohen, Shoshana Revel‐Vilk, Dafna Frydman, et al.
Internal Medicine Journal (2023) Vol. 54, Iss. 3, pp. 398-403
Open Access | Times Cited: 4
Biofabrication of an in-vitro bone model for Gaucher disease
Dishary Banerjee, Margarita M. Ivanova, Nazmiye Celik, et al.
Biofabrication (2023) Vol. 15, Iss. 4, pp. 045023-045023
Open Access | Times Cited: 4
Uncovering a New Family Cluster of Gaucher Disease: A Case Report
Ana Carvoeiro, Miguel Costa, Joana Silva, et al.
Cureus (2024)
Open Access | Times Cited: 1
The Expression and Secretion Profile of TRAP5 Isoforms in Gaucher Disease
Margarita M. Ivanova, Julia Dao, Neala Loynab, et al.
Cells (2024) Vol. 13, Iss. 8, pp. 716-716
Open Access | Times Cited: 1
The Gaucher earlier diagnosis consensus point-scoring system (GED-C PSS): Evaluation of a prototype in Finnish Gaucher disease patients and feasibility of screening retrospective electronic health record data for the recognition of potential undiagnosed patients in Finland
Markku J. Savolainen, Antti Karlsson, Samppa Rohkimainen, et al.
Molecular Genetics and Metabolism Reports (2021) Vol. 27, pp. 100725-100725
Open Access | Times Cited: 10
Highly-sensitive simultaneous quantitation of glucosylsphingosine and galactosylsphingosine in human cerebrospinal fluid by liquid chromatography/tandem mass spectrometry
Shin-ichi Matsumoto, Sho Sato, Kentaro Otake, et al.
Journal of Pharmaceutical and Biomedical Analysis (2022) Vol. 217, pp. 114852-114852
Open Access | Times Cited: 6
Quantitation of a Urinary Profile of Biomarkers in Gaucher Disease Type 1 Patients Using Tandem Mass Spectrometry
Iskren Menkovic, Michel Boutin, Abdulfatah Alayoubi, et al.
Diagnostics (2022) Vol. 12, Iss. 6, pp. 1414-1414
Open Access | Times Cited: 6
Follow-up of pre-motor symptoms of Parkinson’s disease in adult patients with Gaucher disease type 1 and analysis of their lysosomal enzyme profiles in the CSF
Matheus Vernet Machado Bressan Wilke, Fabiano de Oliveira Poswar, Wyllians Vendramini Borelli, et al.
Orphanet Journal of Rare Diseases (2023) Vol. 18, Iss. 1
Open Access | Times Cited: 3
No Evidence That Glucosylsphingosine Is a Biomarker for Parkinson's Disease: Statistical Differences Do Not Necessarily Indicate Biological Significance
Adenrele M. Gleason, Nahid Tayebi, Grisel Lopez, et al.
Movement Disorders (2022) Vol. 37, Iss. 3, pp. 653-653
Open Access | Times Cited: 5
Metabolomic Study Using Time-of-Flight Mass Spectrometry Reveals Novel Urinary Biomarkers for Gaucher Disease Type 1
Iskren Menkovic, Michel Boutin, Abdulfatah Alayoubi, et al.
Journal of Proteome Research (2022) Vol. 21, Iss. 5, pp. 1321-1329
Closed Access | Times Cited: 5
Bone disease in early detected Gaucher Type I disease: A case report
Vincenza Gragnaniello, Alessandro P. Burlina, Renzo Manara, et al.
JIMD Reports (2022) Vol. 63, Iss. 5, pp. 414-419
Open Access | Times Cited: 5
Platelet Activation and Reactivity in a Large Cohort of Patients with Gaucher Disease
Shoshana Revel‐Vilk, Mira Naamad, Dafna Frydman, et al.
Thrombosis and Haemostasis (2021) Vol. 122, Iss. 06, pp. 951-960
Closed Access | Times Cited: 6

Scroll to top